OUR PIPELINE

AP30663

We are developing AP30663 for the acute cardioversion of atrial fibrillation (AF) to sinus rhythm through an intravenous infusion. In a phase 2 trial completed in 2023, SK inhibition with AP30663 resulted in robust cardioversion of AF to sinus rhythm, thereby for the first time demonstrating human efficacy for our novel mechanism of action.

AP31969

We are developing AP31969 for maintenance of sinus rhythm in patients with atrial fibrillation. It is being developed for chronic oral (tablet) treatment.